Home/Rare Diseases/Generalized Pustular Psoriasis

Dermatologic

Generalized Pustular Psoriasis (GPP) Clinical Trials

Also called GPP, Pustular Psoriasis, von Zumbusch Psoriasis, DITRA, IL-36 Receptor Antagonist Deficiency, Acute Generalized Pustular Psoriasis

Ordinary psoriasis makes thick scaly plaques. Generalized pustular psoriasis is driven by a different part of the immune system and looks nothing like it.

View 12 active trialsMatch me to a trial

About Generalized Pustular Psoriasis

Ordinary psoriasis makes thick scaly plaques. Generalized pustular psoriasis is driven by a different part of the immune system and looks nothing like it. The pustules are sterile, meaning they contain white blood cells rather than bacteria, and they are not contagious. The whole body joins in: fever, a racing pulse, swollen skin that hurts to touch. Severe flares can lead to sepsis, dangerous drops in blood pressure, and kidney, lung or heart failure, which is why GPP is treated as a dermatologic emergency.

The engine behind it is a signaling pathway called interleukin-36, or IL-36. Think of IL-36 as an inflammation switch in the skin and a protein called IL-36Ra as the hand that turns it off. In many people with GPP the off switch is weak or missing because of changes in the gene IL36RN. Changes in a second gene, CARD14, do the opposite job and push the inflammation switch on, and a third gene, AP1S3, has also been linked to the disease. When the switch stays on, white blood cells flood the skin and form pustules. Many people with GPP have no detectable change in any of these genes, so the pathway can misfire for reasons that are still being worked out.

Diagnosis rests on the history of how the rash started, the appearance of the skin, and sometimes a skin biopsy. Blood tests alone cannot confirm it. Look-alike conditions include a drug reaction called AGEP and infected eczema, so a dermatologist with experience in pustular disease is worth seeking out.

Common Symptoms of Generalized Pustular Psoriasis

Recognizing the signs of Generalized Pustular Psoriasis early can lead to faster diagnosis and better outcomes. Symptoms may vary in severity from person to person. If you or a loved one are experiencing any of the following, consider speaking with a specialist.

  • Crops of small pus-filled bumps (pustules) on red, tender skin, often across the trunk and limbs
  • Flares that build within a week, with fever, chills, headache and exhaustion
  • Burning, itching and pain in the affected skin
  • Skin that dries, scales and peels as the pustules clear
  • Joint pain, muscle weakness, nausea or diarrhea during a flare
  • Flares that return, from several a year to one every few years, each lasting weeks to months

Who Generalized Pustular Psoriasis Affects

GPP can start at any age but most often appears between 40 and 60, and women are affected slightly more often than men. About 3% of people with psoriasis develop a pustular form, and around half of people with GPP also have plaque psoriasis. People with a change in the IL36RN gene tend to develop it earlier, sometimes in childhood. Flares are often set off by something: an infection, stress, pregnancy (usually in the third trimester), low calcium, certain medicines, and the withdrawal of steroid tablets or injections.

Find Your Next Step

Answer a few questions and we'll point you to the right tools and information for where you are right now.

Where are you in your Generalized Pustular Psoriasis journey?

Side Effect Explorer

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Questions about side effects?
I can help you understand what these reports mean
Tap to start:
Or start with one of these

Genetic Testing

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Generalized Pustular Psoriasis Resources

Reputable organizations and medical references for learning more about Generalized Pustular Psoriasis, including disease registries, foundation resources, and clinical guidelines.

FDA decision ahead
The FDA is due to decide on Imsidolimab (Quimilza) (Vanda Pharmaceuticals) for Generalized pustular psoriasis by December 12, 2026. IL-36 receptor antibody targeting generalized pustular psoriasis flares. Vanda's August 5, 2026 quarterly release refers to the product by the proposed brand name Quimilza and reaffirmed the December 12 target action date.
See all upcoming rare disease FDA decisions →

Active Clinical Trials for Generalized Pustular Psoriasis

Use this Generalized Pustular Psoriasis clinical trial finder to see the 9 studies recruiting patients and 3 opening soon in the United States and worldwide, with eligibility criteria in plain English. These studies play a critical role in advancing care for dermatologic conditions and may offer access to treatments not yet widely available. Each trial below is sourced directly from ClinicalTrials.gov, with eligibility criteria translated into plain English to help patients and caregivers evaluate whether a study may be a fit.

TrialsSite mapPipeline timeline

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

12 active trials worldwide
Filter:
Sort:
RECRUITINGPHASE2Recently updatedNCT07013201

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Intervention: Delgocitinib cream, Vehicle cream

Sponsor: LEO Pharma

The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants w...

Ages 18 Years+40 locations
Started Sep 2025Updated 3 days agoEst. Dec 2026 (~2 months)
RECRUITINGPHASE3Recently updatedNCT07219420

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Intervention: Bimekizumab, Placebo

Sponsor: UCB Biopharma SRL

The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).

Ages 18 Years+91 locations
Started Nov 2025Updated 1 month agoEst. Dec 2027 (~1y 2m)
RECRUITINGRecently updatedNCT06100991

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Sponsor: CorEvitas

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

Ages 18 Years+1 location
Started Sep 2023Updated 1 month agoEst. Dec 2099 (~73y 3m)
NOT YET RECRUITINGPHASE3Recently updatedNCT07530367

Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis

Intervention: Tofacitinib, Imatinib, tofacitinib Placebo, Imatinib Placebo

Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine

Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally. This study aims to evaluate the efficacy and safety of tofacitinib combined with imatinib in patients with moderate-to-severe PPP.

Ages 18 Years+1 location
Started Aug 2026Updated 2 months agoEst. Aug 2028 (~1y 10m)
RECRUITINGNAUpdated a few months agoNCT07552454

Picankibart in Palmoplantar Pustulosis

Intervention: Picankibart

Sponsor: Xijing Hospital

1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to enroll 60 eligible subjects.

2. Study Subjects

Ages 18 Years – 65 Years1 location
Started Apr 2026Updated 5 months agoEst. Oct 2027 (~1 year)
Get an email the day the FDA decides on Imsidolimab

The decision is due December 12. You'll also hear when new Generalized Pustular Psoriasis trials open. Unsubscribe anytime.

We never share your email. Unsubscribe anytime.
Find Generalized Pustular Psoriasis trials near you, ranked by distance →
Active trial locations15 cities in the US
+7 more

Trial Pipeline

Sep 2021 to Oct 2031
2022
2024
2026
2028
2030
now
Phase 2
Phase 3
Phase 4
Observational
Observational
RecruitingOpening soonDelayed startTodayHover a bar for trial details
Need help understanding these trials?
Type your own question with a little about your situation, and get an answer with sources.
Tap to start:
Or start with one of these
Run a Generalized Pustular Psoriasis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Patient Communities

Connect with other Generalized Pustular Psoriasis patients, caregivers, and advocacy groups across Facebook groups, Reddit communities, and YouTube channels. These patient communities offer peer support, shared experiences, caregiver resources, and real-time discussion about Generalized Pustular Psoriasis treatments, clinical trial participation, and day-to-day disease management.

Find the right community
Type your own question with a little about your situation, and get an answer with sources.
Tap to start:
Or start with one of these

Related Dermatologic Conditions

Other rare diseases in the dermatologic category. Patients with Generalized Pustular Psoriasis may find relevant research, shared treatment pathways, or overlapping clinical trials among these related conditions.

Frequently Asked Questions About Generalized Pustular Psoriasis